Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | NPC1 | O15118 | 8/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.68 |
| ▸ | RELA | Q04206 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | ATP4A | P20648 | 1/20 | 0.54 |
| ▸ | ATP4B | P51164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9286493 | 0.83 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2HPGDNFKB1 | |
| SCHEMBL9695000 | 0.82 | TP53 (0.71) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL15653805 | 0.81 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2HPGDNFKB1 | |
| SCHEMBL12604487 | 0.78 | NPC1 (0.73) | RAB9ANPC1SMN1; SMN2HPGDNFKB1 | |
| SCHEMBL10869361 | 0.78 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2HPGDNFKB1 | |
| SCHEMBL6480868 | 0.78 | NPC1 (0.69) | RAB9ANPC1SMN1; SMN2HPGDNFKB1 | |
| SCHEMBL6483534 | 0.78 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2HPGDNFKB1 | |
| Bromide SCHEMBL10768702 | 0.77 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2HPGDNFKB1 | |
| Bromide SCHEMBL10765223 | 0.77 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2HPGDNFKB1 | |
| SCHEMBL11475158 | 0.77 | BCHE (1.00) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5869513-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0649305-A1 | BENZIMIDAZOLES FOR ALLEVIATING STOMACH ULCERS IN SWINE | MONSANTO COMPANY (US) | 1995-04-26 | — | — | EP | disclosed |
| US-5389664-A | Administering benzimidazole compounds to inhibit at pase activity | MONSANTO COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| WO-1994001107-A1 | BENZIMIDAZOLES FOR ALLEVIATING STOMACH ULCERS IN SWINE | MONSANTO COMPANY (US) | 1994-01-20 | — | — | WO | disclosed |
| EP-0204215-A1 | 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines | G.D. Searle & Co. (US) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | RAB9A 486/4885NPC1 363/4885SMN1; SMN2 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.